{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:05:54Z","timestamp":1791137154981,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Amikacin liposome inhalation suspension (ALIS) has been used in several countries including Japan for refractory\n                      <jats:italic>Mycobacterium avium<\/jats:italic>\n                      complex pulmonary disease (MAC-PD). Although its efficacy and adverse events have been reported, factors that limit optimal treatment outcomes in real-world practice are not fully understood. Therefore, we aimed to provide practical considerations for optimizing ALIS therapy by identifying factors associated with culture conversion.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed the medical records of patients with refractory MAC-PD who were treated with ALIS at a single center between October 2021 and June 2025. Patients treated for \u2265\u20096 months were included and categorized into culture conversion and non-conversion groups. Clinical characteristics and treatment-related factors were analyzed. Follow-up continued until December 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      During the study period, 30 patients with refractory MAC-PD were treated with ALIS. Three patients who discontinued ALIS within 6 months were excluded from further analysis because of MAC-related death (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20091) or severe ALIS-related adverse events (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092). Consequently, 27 patients were included in the analysis. The median age was 69.9 years, and the median duration of ALIS therapy was 14.6 months. The sputum culture conversion rate was 51.8% (14\/27; 95% CI, 34.0-69.3%). Pulmonary fungal disease was identified in 7 patients (25.9%), including newly diagnosed cases during ALIS therapy; however, pulmonary fungal disease was not significantly associated with culture conversion. Cavitary lesions and prior aminoglycoside use were significantly associated with non-conversion. In addition, inappropriate ALIS administration, including prolonged intermittent use and inadequate nebulizer handset replacement, was significantly associated with non-conversion. Dysphonia was the most frequent adverse event and occasionally led to prolonged intermittent use of ALIS. ALIS-related lung abnormalities on computed tomography (CT) scans were observed in 21 of 26 patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Cavitary lesions, prior aminoglycoside use, and inappropriate ALIS administration were associated with culture non-conversion. Several factors related to ALIS administration and inhalation management may be modifiable, and appropriate patient education, regular reassessment of inhalation practices, and careful monitoring of ALIS administration may help optimize treatment outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12890-026-04413-w","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T12:53:28Z","timestamp":1781096008000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical factors and practical strategies to optimize amikacin liposome inhalation suspension therapy in refractory Mycobacterium avium complex pulmonary disease"],"prefix":"10.1186","volume":"26","author":[{"given":"Fumio","family":"Kurosaki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Takigami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Kurosaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Hisata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Mato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Maemondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"4413_CR1","doi-asserted-by":"publisher","first-page":"1702469","DOI":"10.1183\/13993003.02469-2017","volume":"51","author":"M Shteinberg","year":"2018","unstructured":"Shteinberg M, Stein N, Adir Y, Ken-Dror S, Shitrit D, Bendayan D, et al. Prevalence, risk factors and prognosis of nontuberculous mycobacterial infection among people with bronchiectasis: a population survey. Eur Respir J. 2018;51:1702469.","journal-title":"Eur Respir J"},{"key":"4413_CR2","doi-asserted-by":"publisher","first-page":"00337","DOI":"10.1183\/23120541.00337-2024","volume":"11","author":"Y Hamaguchi","year":"2025","unstructured":"Hamaguchi Y, Morimoto K, Mitarai S. Laboratory-based surveillance of nontuberculous mycobacterial pulmonary disease in Japan. ERJ Open Res. 2025;11:00337\u20132024.","journal-title":"ERJ Open Res"},{"key":"4413_CR3","unstructured":"Portal Site of Official Statistics of Japan (e-Stat). Vital Statistics: Final Data on Deaths, 2024. https:\/\/www.e-stat.go.jp\/stat-search\/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&year=20240&month=0&tclass1=000001053058&tclass2=000001053061&tclass3=000001053073&tclass4=000001053082&stat_infid=000040316659&result_back=1&cycle_facet=tclass1%3Atclass2%3Atclass3%3Atclass4&tclass5val=0 Accessed 31 March 2026."},{"key":"4413_CR4","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","volume":"71","author":"CL Daley","year":"2020","unstructured":"Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ Jr, Andrejak C, et al. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS\/ERS\/ESCMID\/IDSA Clinical Practice Guideline. Clin Infect Dis. 2020;71:e1\u201336.","journal-title":"Clin Infect Dis"},{"key":"4413_CR5","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.chest.2018.01.024","volume":"153","author":"R Diel","year":"2018","unstructured":"Diel R, Nienhaus A, Ringshausen FC, Richter E, Welte T, Rabe KF, et al. Microbiologic Outcome of Interventions Against Mycobacterium avium Complex Pulmonary Disease: A Systematic Review. Chest. 2018;153:888\u2013921.","journal-title":"Chest"},{"key":"4413_CR6","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","volume":"198","author":"DE Griffith","year":"2018","unstructured":"Griffith DE, Eagle G, Thomson R, Aksamit TR, Hasegawa N, Morimoto K, et al. Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT). A Prospective, Open-Label, Randomized Study. Am J Respir Crit Care Med. 2018;198:1559\u201369.","journal-title":"Am J Respir Crit Care Med"},{"key":"4413_CR7","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3389\/fmicb.2018.00915","volume":"9","author":"J Zhang","year":"2018","unstructured":"Zhang J, Leifer F, Rose S, Chun DY, Thaisz J, Herr T, et al. Amikacin Liposome Inhalation Suspension (ALIS) Penetrates Non-tuberculous Mycobacterial Biofilms and Enhances Amikacin Uptake Into Macrophages. Front Microbiol. 2018;9:915.","journal-title":"Front Microbiol"},{"key":"4413_CR8","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1186\/s12890-024-03261-w","volume":"24","author":"N Urabe","year":"2024","unstructured":"Urabe N, Sakamoto S, Tokita N, Yoshida H, Usui Y, Shimizu H, et al. Effectiveness of Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex pulmonary disease at 6 months post initiation. BMC Pulm Med. 2024;24:442.","journal-title":"BMC Pulm Med"},{"key":"4413_CR9","doi-asserted-by":"publisher","first-page":"ofaf118","DOI":"10.1093\/ofid\/ofaf118","volume":"12","author":"Y Kurahara","year":"2025","unstructured":"Kurahara Y, Yoshida S, Osugi A, Tanaka Y, Kobayashi T, Mitsuhashi T, et al. Effects of Amikacin Liposome Inhalation Suspension and Amikacin Resistance Development in Patients With Refractory Mycobacterium avium Complex Pulmonary Disease. Open Forum Infect Dis. 2025;12:ofaf118.","journal-title":"Open Forum Infect Dis"},{"key":"4413_CR10","doi-asserted-by":"publisher","first-page":"108408","DOI":"10.1016\/j.rmed.2025.108408","volume":"248","author":"N Tokita","year":"2025","unstructured":"Tokita N, Ito M, Urabe N, Fujiwara K, Furuuchi K, Kodama T, et al. Real-world effectiveness and lung abnormalities associated with amikacin liposome inhalation suspension. Respir Med. 2025;248:108408.","journal-title":"Respir Med"},{"key":"4413_CR11","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.resinv.2025.04.005","volume":"63","author":"T Takazono","year":"2025","unstructured":"Takazono T, Tashiro M, Izumikawa K, Mukae H. Challenges in the diagnosis and treatment of chronic pulmonary aspergillosis in Japan. Respir Investig. 2025;63:488\u201394.","journal-title":"Respir Investig"},{"key":"4413_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1183\/13993003.00583-2015","volume":"47","author":"DW Denning","year":"2016","unstructured":"Denning DW, Cadranel J, Beigelman-Aubry C, Ader F, Chakrabarti A, Blot S, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J. 2016;47:45\u201368.","journal-title":"Eur Respir J"},{"key":"4413_CR13","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events\/ctcae-v5-8x11.pdf Accessed 1 May 2026."},{"issue":"4","key":"4413_CR14","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1093\/annalsats\/aaoaf064","volume":"23","author":"CL Daley","year":"2026","unstructured":"Daley CL, van Ingen J, Chalmers JD, Flume PA, Griffith DE, Hasegawa N, et al. Amikacin liposome inhalation suspension in newly diagnosed Mycobacterium avium complex lung disease (ARISE): a 6-month double-blind, active comparator trial. Ann Am Thorac Soc. 2026;23(4):536\u201347.","journal-title":"Ann Am Thorac Soc"},{"key":"4413_CR15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.prp.2011.10.001","volume":"208","author":"K Hibiya","year":"2012","unstructured":"Hibiya K, Shigeto E, Iida K, Kaibai M, Higa F, Tateyama M, et al. Distribution of mycobacterial antigen based on differences of histological characteristics in pulmonary Mycobacterium avium infectious diseases\u2013consideration of the extent of surgical resection from the pathological standpoint. Pathol Res Pract. 2012;208:53\u20138.","journal-title":"Pathol Res Pract"},{"key":"4413_CR16","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1016\/j.chest.2022.09.037","volume":"163","author":"JY Kim","year":"2023","unstructured":"Kim JY, Lee HW, Yim JJ, Kwak N. Outcomes of Adjunctive Surgery in Patients With Nontuberculous Mycobacterial Pulmonary Disease: A Systematic Review and Meta-analysis. Chest. 2023;163:763\u201377.","journal-title":"Chest"},{"key":"4413_CR17","unstructured":"ARIKAYCE drug information. Instructions for Use: https:\/\/www.arikayce.com\/pdf\/instructions_for_use.pdf Accessed 31 March 2026."},{"key":"4413_CR18","unstructured":"ARIKAYCE drug information. Prescribing information: https:\/\/www.arikayce.com\/pdf\/full_prescribing_information.pdf Accessed 31 March 2026."},{"key":"4413_CR19","doi-asserted-by":"publisher","first-page":"872","DOI":"10.5588\/ijtld.23.0275","volume":"27","author":"Y Kurahara","year":"2023","unstructured":"Kurahara Y, Kanaoka K, Tanaka Y, Maeda Y, Kobayashi T, Takeuchi N, et al. Management of dysphonia caused by amikacin liposome inhalation in M. avium complex pulmonary disease. Int J Tuberc Lung Dis. 2023;27:872\u20133.","journal-title":"Int J Tuberc Lung Dis"},{"key":"4413_CR20","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1136\/thoraxjnl-2012-201772","volume":"68","author":"C Andr\u00e9jak","year":"2013","unstructured":"Andr\u00e9jak C, Nielsen R, Thomsen V\u00d8, Duhaut P, S\u00f8rensen HT, Thomsen RW. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax. 2013;68:256\u201362.","journal-title":"Thorax"},{"key":"4413_CR21","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.2169\/internalmedicine.8796-21","volume":"61","author":"M Kidogawa","year":"2022","unstructured":"Kidogawa M, Yamasaki K, Nemoto K, Yatera K. Liposomal Amikacin Inhalation Suspension-induced Pneumonitis. Intern Med. 2022;61:2547\u20139.","journal-title":"Intern Med"},{"key":"4413_CR22","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.resinv.2024.04.003","volume":"62","author":"T Kaneko","year":"2024","unstructured":"Kaneko T, Otoshi R, Sekine A, Baba T, Yamada C, Haga S, et al. Drug-related pneumonitis caused by amikacin liposome inhalation suspension: One pathologically proven case and single-center experience. Respir Investig. 2024;62:513\u20136.","journal-title":"Respir Investig"},{"key":"4413_CR23","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1016\/j.jiac.2018.04.002","volume":"24","author":"K Furuuchi","year":"2018","unstructured":"Furuuchi K, Ito A, Hashimoto T, Kumagai S, Ishida T. Risk stratification for the development of chronic pulmonary aspergillosis in patients with Mycobacterium avium complex lung disease. J Infect Chemother. 2018;24:654\u20139.","journal-title":"J Infect Chemother"},{"key":"4413_CR24","doi-asserted-by":"publisher","first-page":"e70083","DOI":"10.1111\/myc.70083","volume":"68","author":"Y Tanaka","year":"2025","unstructured":"Tanaka Y, Ide S, Takazono T, Takeda K, Iwanaga N, Yoshida M, et al. Risk Factors and Long-Term Prognosis for Coinfection of Nontuberculous Mycobacterial Pulmonary Disease and Chronic Pulmonary Aspergillosis: A Multicentre Observational Study in Japan. Mycoses. 2025;68:e70083.","journal-title":"Mycoses"},{"key":"4413_CR25","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3390\/microorganisms9020270","volume":"9","author":"K Fukushima","year":"2021","unstructured":"Fukushima K, Kida H. New\/Different Look at the Presence of Aspergillus in Mycobacterial Pulmonary Diseases. Long-Term Retrospective Cohort Study. Microorganisms. 2021;9:270.","journal-title":"Microorganisms"},{"key":"4413_CR26","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1473-3099(24)00567-X","volume":"25","author":"A Sengupta","year":"2025","unstructured":"Sengupta A, Ray A, Upadhyay AD, Izumikawa K, Tashiro M, Kimura Y, et al. Mortality in chronic pulmonary aspergillosis: a systematic review and individual patient data meta-analysis. Lancet Infect Dis. 2025;25:312\u201324.","journal-title":"Lancet Infect Dis"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-026-04413-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04413-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-026-04413-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T10:46:42Z","timestamp":1788000402000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12890-026-04413-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4413"],"URL":"https:\/\/doi.org\/10.1186\/s12890-026-04413-w","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"11 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Table 4 has been updated to properly aligned with the corresponding management strategies.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by Jichi Medical University Hospital Bioethics Committee for Clinical Research (Approval No. Rindai 24\u2013218). The requirement for informed consent was waived due to the retrospective nature of the study, and patients and their families were given the opportunity to opt out.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"FK (Fumio Kurosaki, the first author) has received lecture fees from Insmed Inc. The other authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"356"}}